ArticleExploration (Beijing, China)2026
Immunosuppressive Microenvironment Reprogramming by Synergistic Sonodynamic Therapy of Phthalocyanine-MOF Hybrids for Hepatocellular Carcinoma.
Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Glutathione-Induced In Situ Oxygen Vacancies in FeOOH Nanospindles for Boosting Sonocatalytic Tumor Therapy.Angewandte Chemie (International ed. in English) · 2026Article
- Rational Design of Controlled Aroma Delivery Systems for Bioactive Applications.Advanced healthcare materials · 2026Review
- Biomimetic PD-1-Functionalized Immunostimulatory Nanomedicine Enables STING Activation and Durable Antitumor Immunity in Hepatocellular Carcinoma.Nano-micro letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a critical global health challenge with limited treatment efficacy hindered by therapy resistance and hypoxia-induced immune suppression. Tumor heterogeneity and low immune cell reactivity often lead to tolerance and failure of immunotherapy. Sonodynamic therapy (SDT) has emerged as a promising precision treatment with non-invasive characteristics and localized tumor targeting, offering potential for remodeling the immunosuppressive tumor microenvironment. This study introduces a novel phthalocyanine-metal-organic framework hybrid (Pc@Zr-MOF) designed for SDT and immune regulation in HCC. By enhancing the efficiency of ultrasonic conversion and synergy, Pc@Zr-MOF induces robust tumor cell apoptosis while simultaneously reshaping the immune landscape. Single-cell RNA sequencing reveals its ability to promote M1 macrophage polarization and increase cytotoxic T cell infiltration with tumor-associated macrophages. These effects highlight its dual mechanism of direct tumor eradication and immune microenvironment remodeling. Moreover, Pc@Zr-MOF demonstrates admirable biocompatibility and minimal off-target toxicity, which underscores its clinical translational potential. By synergizing SDT with immune reprogramming, this approach addresses hypoxia-driven resistance and establishes durable anti-tumor immunity. This study aims to change the current situation of advanced HCC treatment characterized by reconfiguration of tumor cell subpopulations and immunosuppression, thereby bringing a new paradigm to the precise treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.